Latest revenue
$3.1M
as of 2022-09-30
Latest net income
$-7.6M
as of 2022-09-30
Net margin
-245.5%
as of 2022-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think APVO is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $5.9M
- Enterprise value
- $14.5M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 0.51×
- Dividend yield
- 0.0%
- 52-wk high
- $13.11
- 52-wk low
- $0.50
- Beta
- —
- Shares out
- 1.2M
5-year trend
What this company does
Item 1. Business. OVERVIEW We are a clinical-stage, research and development biotechnology company focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. We have developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs and have two clinical candidates and six preclinical candidates currently in development. Clinical candidate mipletamig is a CD123xCD3 T cell engager currently being clinically evaluated in the RAINIER trail, part one of a Phase 1b/2 program initiated in August 2024 for the treatment of frontline acute myelogenous leukemia (AML) in combination with standard of care…
AI summary unavailable — showing raw filing excerpt
Generated from APVO's filing dated 2026-03-26
Key risks
Item 1A. Risk Factors. We are subject to significant risks and uncertainties that could impact the Company’s businesses, results of operations and financial condition, including by causing our actual results to differ materially from those projected in any forward-looking statements. Additional risks and uncertainties that are not currently known to the Company or management or that are not currently believed by the Company or management to be material may also harm the Company’s business, financial condition and results of operation. You should carefully consider the following risks and other information in this Annual Report on Form 10-K in evaluating us and our common stock. RISK FACTOR…
AI summary unavailable — showing raw filing excerpt
Generated from APVO's filing dated 2026-03-26
Profitability
Operating margin
-919.7%
428.3%Net margin
257.8%
211.3%Return on equity
-149.4%
70.6%Return on assets
-95.5%
38.3%Leverage
Debt / equity
0.56×
75.2%Long-term debt / equity
0.08×
97.3%Debt / assets
36.1%
48.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q4 2025 2025-12-31 | — | — | $-5.8M | +8.0% | — |
Q3 2025 2025-09-30 | — | — | $-7.5M | -48.0% | — |
Q2 2025 2025-06-30 | — | — | $-6.2M | -5.5% | — |
Q1 2025 2025-03-31 | — | — | $-6.4M | +6.2% | — |
Q4 2024 2024-12-31 | — | — | $-6.3M | — | — |
Q3 2024 2024-09-30 | — | — | $-5.1M | +19.5% | — |
Q2 2024 2024-06-30 | — | — | $-5.9M | -13.7% | — |
Q1 2024 2024-03-31 | — | — | $-6.8M | — | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on APVO — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$20.1K
Insider selling
$0
Net activity
+$20.1K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns APVO
Institutional value
$87.2K
Total shares held
40.0K
Distinct holders
6
-5 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 12.7K | $54.3K | — | New |
| 2 | VANGUARD FIDUCIARY TRUST CO | 4.1K | $17.7K | — | New |
| 3 | UBS Group AG | 3.4K | $14.7K | +3.3K (+1926.5%) | Added |
| 4 | SBI Securities Co., Ltd. | 109 | $465 | +78 (+251.6%) | Added |
| 5 | GSA CAPITAL PARTNERS LLP | 19.6K | $84 | — | New |
| 6 | DANSKE BANK A/S | 1 | $4 | +0 (+0.0%) | No change |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once APVO's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.